Composition for promoting growth and development and application thereof

Abstract

The invention discloses a composition for promoting growth and development and application thereof, and relates to the technical field of nutritional compositions. The invention provides a composition for promoting growth and development, the composition is composed of milk mineral salt, colostrum basic protein and hydrolyzed egg yolk powder, and the mass ratio of the milk mineral salt to the colostrum basic protein to the hydrolyzed egg yolk powder is (14-22): (5-10): 1. The composition provided by the invention can promote growth and development, can increase the fluorescence intensity of the skull of the zebra fish and increase the body length of the zebra fish, and has an obvious effect on promoting skeletal development and body development.

Description

Technical Field

[0001] The present invention relates to the technical field of nutritional compositions, and particularly to compositions for promoting growth and development and their applications. Background Art

[0002] Growth and development is a continuous, phased, dynamic and complex process, with different characteristics in different stages. The meaning of growth includes two major aspects, not only including the changes in the quantity, size and weight of cells, tissues and organs, but also including the changes in the chemical components of cells, tissues, organs and systems, that is, morphological growth and chemical growth. Development, including both physical and mental aspects, refers to the process in which body tissues, organs and systems are continuously differentiated and improved in function. The growth and development level of children can reflect the nutritional and health status of individuals. The process of children's growth and development is jointly affected by genetic factors and environmental factors, and various factors can hinder children's growth and development to varying degrees.

[0003] The growth and development level of children is closely affected by nutritional status. Malnutrition or overnutrition will have adverse effects on children's physical health and intellectual development. In the long run, the growth and poor development of children will reduce their ability to resist diseases.

[0004] Chinese Patent CN113180117A discloses a modified milk powder for promoting children's digestion and growth and development. The modified milk powder is composed of the following components in parts by weight: 30-50 parts of whole milk powder, 20-30 parts of skim milk powder, 10-20 parts of demineralized whey powder, 8-15 parts of solid corn syrup, 0.01-0.09 part of colostrum basic protein powder, 0.3-1.5 parts of milk mineral salts, 0.2-0.6 part of plant calcium source, 0.01-0.1 part of taurine, 0.2-0.4 part of vitamins, and 0.8-1.5 parts of minerals. The modified milk powder of the invention has the effects of regulating the spleen and stomach, promoting digestion, promoting growth and development, etc., and can promote the health of children's digestive tract from three dimensions of digestion, health and moistening; it promotes children's growth and development through the synergistic effects of supplementing nutrients and digestive tract health.

[0005] Chinese Patent CN115317581A discloses a pharmaceutical composition for promoting the growth and development of children and its preparation method, which is composed of the following components in parts by weight: 15-20 parts of fructus amomi extract, 7-10 parts of seabuckthorn extract, 7-10 parts of codonopsis pilosula extract, 7-10 parts of mulberry fruit extract, 7-10 parts of poria cocos extract, 0.2-0.5 parts of vitamin A, and 0.5-1.0 parts of vitamin D. The composition of the invention adds vitamin A and D, and the presence of other traditional Chinese medicine extracts plays an auxiliary role in promoting the absorption of vitamin A and D, and at the same time has the effects of tonifying the middle qi and strengthening the muscles and spleen. Taking the pharmaceutical composition of the invention can increase the levels of 25-(OH)D and osteocalcin in children. However, the drug form has a low acceptance degree among children.

[0006] At present, there is a need to provide a composition that is rich in nutrients, has a high acceptance degree, and can meet the growth and development needs, to provide the nutritional needs during the growth and development stage. Summary of the Invention

[0007] The object of the present invention is to provide a composition for promoting growth and development and its application.

[0008] To achieve the above object of the invention, the technical solution of the present invention is as follows:

[0009] On the one hand, the present invention provides a composition for promoting growth and development, which is composed of milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder, and the mass ratio of the milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder is (14-22):(5-10):1.

[0010] Further, the mass ratio of the milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder is 14-20:5-8:1.

[0011] Further, the mass ratio of the milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder is 20:8:1.

[0012] Specifically, the composition may further include excipients.

[0013] Further, the excipients are selected from one or more of whole milk powder, skim milk powder, whey protein powder, lactose, calcium, minerals, vitamins, docosahexaenoic acid powder, arachidonic acid powder, probiotics, galactooligosaccharides, and 2'-fucosyllactose.

[0014] Specifically, the probiotics are selected from one or more of bifidobacterium animalis subsp. lactis, lactobacillus acidophilus, lactobacillus casei, bifidobacterium longum, bifidobacterium breve, and bacillus coagulans;

[0015] Further, the probiotic is bifidobacterium animalis subsp. lactis.

[0016] According to some embodiments of the present invention, the excipients in the composition of the present invention include whole milk powder, skim milk powder, whey protein powder, lactose, calcium, minerals, compound vitamins, docosahexaenoic acid powder, arachidonic acid powder, Bifidobacterium animalis subsp. lactis, milk mineral salts, and 2'-fucosyllactose.

[0017] In another aspect, the present invention provides a method for preparing the above composition, comprising the following steps: making the respective raw materials after being mixed evenly.

[0018] In another aspect, the present invention provides the application of the above composition in the preparation of products for promoting growth and development.

[0019] Specifically, the said product can promote bone growth and height increase.

[0020] Furthermore, the said product can promote bone growth and height increase in children or adolescents.

[0021] Specifically, the said product is a medicine or food.

[0022] Furthermore, the said food is in the form of dairy products.

[0023] Still further, the said food is in the form of milk powder or liquid dairy products.

[0024] Specifically, the said food is infant food.

[0025] Furthermore, the dosage form of the said food is tablets, capsules, powders, granules, pills, or oral liquids.

[0026] Furthermore, the said food may further include excipients acceptable in food science.

[0027] Still further, the excipients acceptable in food science are selected from one or more of sweeteners, flavoring agents, colorants, stabilizers, glidants, fillers, surfactants, carbohydrates, antioxidants, chelating agents, preservatives, carriers, wetting agents, isotonizing agents, solvents, emulsifiers.

[0028] Furthermore, when the said product is a medicine, the said medicine may include carriers acceptable in pharmacy.

[0029] Still further, the carriers acceptable in pharmacy are selected from one or more of buffers, emulsifiers, stabilizers, diluents, binders, preservatives, pH regulators, flavoring agents.

[0030] Specifically, the said buffer is selected from at least one of sodium dihydrogen phosphate, sodium bicarbonate, ammonium bicarbonate, sodium acetate, citrate, histidine, succinate.

[0031] Specifically, the emulsifier is selected from at least one of magnesium stearate, zinc stearate, calcium stearate, glyceryl stearate, sorbitan isostearate, sorbitan oleate, glyceryl oleate, polyglyceryl-3 polyricinoleate.

[0032] Specifically, the stabilizer is selected from at least one of acacia gum, agar, alginic acid, cellulose ether, carboxymethyl chitin ester.

[0033] Specifically, the diluent is selected from at least one of erythritol, mannitol, sorbitol, xylitol, lactose, sucrose, corn starch, potato starch, calcium phosphate, calcium citrate, crystalline cellulose.

[0034] Specifically, the binder is selected from at least one of ethanol, starch paste, pregelatinized starch, dextrin, syrup, hydroxypropyl methylcellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyvinyl alcohol, polyethylene glycol, sodium alginate, polyvinylpyrrolidone, gum arabic, gelatin, alginic acid.

[0035] Specifically, the preservative is selected from at least one of methyl paraben, propyl paraben, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, chlorobutanol, thimerosal, mercuric oxycyanide, phenoxyethanol, chlorhexidine, benzoic acid, sodium benzoate, chlorocresol, benzalkonium bromide, benzalkonium chloride, ethylparaben.

[0036] Specifically, the pH regulator is selected from at least one of citric acid, fumaric acid, succinic acid, tartaric acid, malic acid and ascorbic acid.

[0037] Specifically, the flavoring agent is selected from at least one of sweet orange flavor, vanilla flavor, strawberry flavor, milk flavor, banana flavor, cherry flavor.

[0038] Specifically, when the product is a drug, the dosage form of the drug is drops, mixture, tincture, injection, tablet, powder, oral liquid, capsule, granule, ointment, suspension, powder, emulsion, solution, dripping pill, pill, buccal tablet, lyophilized powder for injection, gel, suppository or aerosol.

[0039] The beneficial effects of the present invention are as follows:

[0040] The composition with a specific ratio composed of milk mineral salts, colostrum basic protein and hydrolyzed egg yolk powder provided by the present invention can promote growth and development, increase the fluorescence intensity of zebrafish skulls and increase the body length of zebrafish, and has obvious effects on promoting bone development and body development. Detailed implementation mode

[0041] In order to make the technical means, creative features, achieved purposes and effects of the present invention easy to understand, the present invention will be further clarified below in conjunction with specific embodiments. However, the following embodiments are only the preferred embodiments of the present invention, not all of them. Based on the embodiments in the implementation manner, other embodiments obtained by those skilled in the art without creative efforts all fall within the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operation methods used are all conventional operation methods, the equipment used is all conventional equipment, and the equipment materials used in each embodiment are the same.

[0042] Example 1

[0043] 1. Test materials

[0044] 1.1 Sample preparation information

[0045] The CBP composition of Example 1 is milk mineral salts + colostrum basic protein + hydrolyzed egg yolk powder, and the mass ratio of milk mineral salts, colostrum basic protein and hydrolyzed egg yolk powder is 20:8:1.

[0046] Commercially available pure milk is directly added in liquid form. (Note: The concentration of commercially available pure milk is measured by the Ca content, and the original liquid Ca content is 100 mg / 100 mL).

[0047] Preparation method of the CBP composition: It is made by mixing each raw material evenly.

[0048] The normal control group is the standard dilution water treatment group.

[0049] 1.2 Experimental animals

[0050] Zebrafish are all raised in fish-raising water at 28°C (water quality: 200 mg of instant sea salt is added to every 1 L of reverse osmosis water, the conductivity is 450 - 550 μS / cm; the pH is 6.5 - 8.5; the hardness is 50 - 100 mg / L CaCO 3 )), provided by the fish-raising center, the experimental animal use license number is: SYXK(Zhe)2022 - 0004, the feeding management meets the requirements of international AAALAC certification (certification number: 001458), and the IACUC ethical review number is: IACUC - 2024 - 10692 - 01.

[0051] 1.3 Instruments, consumables and reagents

[0052] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); Electrically focused continuously variable fluorescence microscope (AZ100, Nikon, Japan); Precision electronic balance (CP214, OHAUS, America); 6-well plate (Zhejiang Beilamber Biotechnology Co., Ltd., China); Ultrasonic cleaner (JP-010T, Shenzhen Jiemeng Cleaning Equipment Co., Ltd., China); Digital display horizontal decolorizing shaker (ZD-9556A, Taicang Hualida Experimental Equipment Co., Ltd., China); Automatic sample rapid grinder (JXFSTPRP-24L, Shanghai Jingxin Experimental Equipment Science and Technology Department, China).

[0053] Methyl cellulose (batch number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Sodium percarbonate (batch number D1827013, Shanghai Aladdin Biochemical Technology Co., Ltd., China); 4% tissue cell fixative (batch number 2308002, Beijing Solarbio Science & Technology Co., Ltd., China); Alizarin red (batch number C12071107, Shanghai Macklin Biochemical Co., Ltd., China); Anhydrous magnesium chloride (batch number C1809044, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Potassium hydroxide (batch number T20110104, Sinopharm Chemical Reagent Co., Ltd., China); Glycerol (batch number B23031446, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Absolute ethanol (batch number 20240123, Sinopharm Chemical Reagent Co., Ltd., China); Hydrogen peroxide W5 (batch number 20210203, Sinopharm Chemical Reagent Co., Ltd., China); PBS phosphate buffer (dry powder) (batch number 23045283, Biosharp, China).

[0054] 2. Detection method

[0055] 2.1 Evaluation of the efficacy of promoting bone development

[0056] Randomly select 3-dpf wild-type AB strain zebrafish into beakers, with 30 zebrafish in each beaker (experimental group). Administer the sample in aqueous solution (concentration is shown in Table 1), and at the same time set up a normal control group. Sodium percarbonate is added as an oxygenating agent to all groups, and the capacity of each beaker is 20 mL. Change the liquid every day. After treatment at 28 °C for 3 days, collect the samples and perform alizarin red staining. Randomly select 10 zebrafish from each experimental group and place them under a fluorescence microscope for photographing. Use NIS-Elements D3.20 advanced image processing software to analyze and collect data, analyze the fluorescence intensity (S) of the zebrafish skull, and evaluate the effect (B) of the sample on bone development and the efficacy of the sample in promoting bone development (bone density) based on the statistical analysis results of this index. The statistical processing results are expressed as mean ± SE.

[0057] The calculation formula is as follows:

[0058]

[0059] The efficacy of the sample in promoting bone development (%) = B (sample group) - B (normal control group).

[0060] Perform statistical analysis using SPSS 26.0 software. p < 0.05 indicates that the difference is statistically significant. The specific statistical methods are as follows: Explore the data, and obtain the exploration results from the K-S test. If the p value of the normality test > 0.05 (i.e., it follows a normal distribution), then use the independent samples T test in parametric tests for statistical analysis; if the p value of the normality test < 0.05 (i.e., it does not follow a normal distribution), then use the two independent samples in non-parametric tests for statistical analysis.

[0061] 2.2 Evaluation of the Efficacy in Promoting Body Development (Body Length)

[0062] Randomly select 3-dpf wild-type AB strain zebrafish into beakers, with 30 zebrafish in each beaker (experimental group). Administer the sample in aqueous solution (concentration is shown in Table 2), and at the same time set up a normal control group. Sodium percarbonate is added as an oxygenating agent to all groups, and the capacity of each beaker is 20 mL. Change the liquid every day. After treatment at 28 °C for 3 days, randomly select 10 zebrafish from each experimental group and place them under a dissection microscope for photographing. Use Image J advanced image processing software to analyze and collect data, analyze the body length (L) of the zebrafish, and evaluate the effect (H) of the sample on body development and the efficacy of the sample in promoting body development (body length) based on the statistical analysis results of this index. The statistical processing results are expressed as mean ± SE. The calculation formula for the efficacy of the sample in promoting body development is as follows:

[0063]

[0064] The efficacy of the sample in promoting body development (%) = H (sample group) - H (normal control group).

[0065] Statistical analysis was performed using SPSS 26.0 software. A p-value < 0.05 indicates statistical significance. The specific statistical methods are as follows: Explore the data, and obtain the exploration results from the K-S test. If the p-value of the normality test > 0.05 (i.e., follows a normal distribution), then use the independent samples T-test in parametric tests for statistical analysis; if the p-value of the normality test < 0.05 (i.e., does not follow a normal distribution), then use two independent samples in non-parametric tests for statistical analysis.

[0066] 3. Test Results

[0067] 3.1 Evaluation of the Efficacy in Promoting Bone Development

[0068] It can be seen from the following table: (1) The CBP composition has the efficacy in promoting bone development, specifically manifested as an increase in the fluorescence intensity of the skull; the efficacy of pure milk in promoting bone development is not obvious. (2) When comparing between the two concentrations of each sample, the fluorescence intensity of the skull in the CBP composition group at 14 μg / mL and 70.0 μg / mL concentrations is significantly higher than that of the pure milk group; (3) At a concentration of 14.0 μg / mL, the efficacy of the CBP composition in promoting bone development is 21.90%, significantly higher than 4.72% of the pure milk group; (4) At a concentration of 70.0 μg / mL, the efficacy of the CBP composition in promoting bone development is 25.92%, significantly higher than 6.25% of the pure milk group. See Table 1 for details.

[0069] Table 1 Experimental Results of the Efficacy Evaluation of Samples in Promoting Bone Development (n = 10)

[0070]

[0071] Compared with the normal control group, *p < 0.05, **p < 0.01;

[0072] Compared with the CBP composition at 14.0 μg / mL, #p < 0.05

[0073] Compared with the CBP composition at 70.0 μg / mL, ^p < 0.05.

[0074] 3.2 Evaluation of the Efficacy in Promoting Body Development (Body Length)

[0075] Under the conditions of this experiment, (1) The CBP composition and pure milk have the efficacy in promoting body development, specifically manifested as an increase in the body length of zebrafish. (2) At a concentration of 14.0 μg / mL, the efficacy of the CBP composition in promoting body development is 2.68%, and the efficacy of the pure milk group in promoting body development is 1.42%. The CBP composition is better than the pure milk group in terms of the efficacy in promoting body development. See Table 2 for details.

[0076] Table 2 Experimental Results of the Efficacy Evaluation of Samples in Promoting Body Development (Body Length) (n = 10)

[0077]

[0078]

[0079] Compared with the normal control group, *p < 0.05, ***p < 0.001.

[0080] Example 2

[0081] The difference between the CBP composition in Example 2 and that in Example 1 is only that the mass ratio of milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder in Sample A of Example 2 is 14:5:1.

[0082] The preparation method is the same as that in Example 1.

[0083] Example 3

[0084] The difference between the CBP composition in Example 3 and that in Example 1 is only that the mass ratio of milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder in Sample A of Example 3 is 22:10:1.

[0085] The preparation method is the same as that in Example 1.

[0086] Comparative Example 1

[0087] The difference between the CBP composition in Comparative Example 1 and that in Example 1 is only that the mass ratio of milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder in Sample A of Comparative Example 1 is 15:1:1.

[0088] The preparation method is the same as that in Example 1.

[0089] Comparative Example 2

[0090] The difference between the CBP composition in Comparative Example 2 and that in Example 1 is only that the mass ratio of milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder in Sample A of Comparative Example 2 is 200:15:1.

[0091] The preparation method is the same as that in Example 1.

[0092] Comparative Example 3

[0093] The difference between the CBP composition in Comparative Example 3 and that in Example 1 is only that the mass ratio of milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder in Sample A of Comparative Example 3 is 8:5:1.

[0094] The preparation method is the same as that in Example 1.

[0095] Comparative Example 4

[0096] Prepare milk powder according to the formula and preparation method of the peptide milk powder disclosed in Example 3 of Chinese Patent Publication No. CN117179060A.

[0097] The detection methods for Examples 2-3 and Comparative Examples 1-4 were the same as those in Example 1 above, and the detection results are as follows:

[0098] Table 3 Experimental results of the evaluation of the efficacy of samples in promoting bone development (n = 10)

[0099]

[0100]

[0101] Note: Compared with the control group, *p < 0.05;

[0102] Compared with Example 1 (CBP composition), #p < 0.05.

[0103] As can be seen from Table 3 above, compared with the normal control group, the CBP compositions of Examples 1-3 can significantly promote the efficacy of bone development, and the efficacy of promoting bone development is 20.40%-21.90%. When the ratios of milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder in Comparative Examples 1-3 are outside the protection scope of the present invention, the efficacy of promoting bone development decreases significantly, significantly lower than that of the group in Example 1. Comparative Example 4 is a milk powder for promoting growth disclosed in the prior art, but as can be seen from the above table, its efficacy in promoting physical development is poor.

[0104] Table 4 Experimental results of the evaluation of the efficacy of samples in promoting physical development (body length) (n = 10)

[0105]

[0106]

[0107] Note: Compared with the control group, *p < 0.05;

[0108] Compared with Example 1 (CBP composition), #p < 0.05.

[0109] As can be seen from Table 4 above, compared with the normal control group, the CBP compositions of Examples 1-3 can significantly promote physical development, and the efficacy of promoting physical development is 2.30%-2.77%. In Comparative Examples 1-3, the ratios of milk mineral salts, colostrum basic protein, and hydrolyzed egg yolk powder are outside the protection scope of the present invention. In Comparative Example 4, it is a disclosed milk powder. However, compared with Example 1, the efficacy of promoting growth and development in the groups of Comparative Examples 1-4 decreases significantly.

[0110] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

Claims

1. A composition for promoting growth and development, characterized in that: The composition consists of milk mineral salt, colostrum alkaline protein and hydrolyzed egg yolk powder, and the mass ratio of the milk mineral salt, colostrum alkaline protein and hydrolyzed egg yolk powder is (14-22): (5-10):

1.

2. The composition according to claim 1, characterized in that The mass ratio of the milk mineral salt, colostrum alkaline protein and hydrolyzed egg yolk powder is 14-20:5-8:

1.

3. The composition according to any one of claims 1 to 2, characterized in that The composition also includes auxiliary materials.

4. The composition according to claim 3, characterized in that The auxiliary materials are selected from one or more of whole milk powder, skim milk powder, whey protein powder, lactose, calcium, minerals, vitamins, docosahexaenoic acid powder, arachidonic acid powder, probiotics, galacto-oligosaccharide and 2'-fucosyllactose.

5. The method for preparing the composition according to any one of claims 1 to 4, characterized in that: The following steps are involved: The raw materials are mixed evenly and then prepared.

6. Use of the composition according to any one of claims 1 to 4 in the preparation of a product for promoting growth and development.

7. The use according to claim 6, characterized in that: The product is capable of promoting bone growth and increasing height.

8. The use according to claim 6, characterized in that: The product described is a pharmaceutical product.

9. The use according to claim 6, characterized in that: The product described is a food.

10. A product for promoting growth and development, characterized in that: The product comprises the composition according to any one of claims 1 to 4.

Images